Minnesota Oncology

Liver Cancer News

Hepatitis C Cases Could Be Cured By Novel Oral Drug Regimen (July 31, 2014)

According to the results of two new clinical studies published in The Lancet, two new pill-only antiviral drug regimens for hepatitis C virus infection provide shorter and more effective treatment options with fewer side effects for most patients affected... Continue Reading

Liver Cancer Drug Livatag® Granted U.S. Food and Drug Administration Fast Track Designation (May 27, 2014)

The drug Livatag® (doxorubicin Transdrug™) has received fast-track designation from the U.S. Food and Drug Administration (FDA) for the treatment of primary liver cancer after treatment with Nexavar® (sorafenib). This was recently announced in a press... Continue Reading

Coffee Cuts Risk of Liver Cancer (November 8, 2013)

Good news for coffee addicts—new research has found that regular coffee consumption can reduce the risk of liver cancer by 40 percent. In fact, the study—published in Clinical Gastroenterology and Hepatology—found that people who consume more than... Continue Reading

End-of-Life Care Remains Aggressive, Despite Patient Wishes (September 16, 2013)

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact, elderly patients with advanced cancer often receive... Continue Reading

Following Lifestyle Recommendations Reduces Risk of Cancer Death (May 15, 2013)

People who follow the diet and lifestyle recommendations laid out by the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) have a 34 percent reduced risk of dying from several diseases and specifically, a 20 percent... Continue Reading

Statins Linked to Lower Risk of Liver Cancer in Hepatitis C (May 8, 2013)

People infected with chronic hepatitis C are less likely to develop liver cancer if they are taking statins (cholesterol-lowering drugs), according to the results of a study published in the Journal of Clinical Oncology.[1] The liver is the largest organ... Continue Reading

Cancer Deaths on the Decline (February 11, 2013)

Overall cancer death rates continue to decline in both men and women and across major ethnic and racial groups, according to the annual Status of Cancer report published in the Journal of the National Cancer Institute. What’s more—cancer incidence... Continue Reading

Antiviral Therapy May Reduce the Risk of Tumor Recurrence in HBV-Related Liver Cancer (November 26, 2012)

Patients with hepatitis B-related liver cancer who receive antiviral drugs after curative surgery have a lower risk of recurrence compared to those who do not receive antiviral therapy, according to the results of a study published in the Journal of the... Continue Reading

Approximately 16% of Worldwide Cancers Caused By Preventable Infections (May 17, 2012)

Two million cancer cases each year—or roughly 16 percent of cancers worldwide—are the result of preventable and treatable infections such as human papillomavirus (HPV) and Hepatitis C (HCV), according to the results of a study published in The Lancet... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

Latest Liver Cancer News By Stage


Hepatocellular Carcinoma Liver Cancer

Antiviral Therapy May Reduce the Risk of Tumor Recurrence in HBV-Related Liver Cancer (November 26, 2012)

Patients with hepatitis B-related liver cancer who receive antiviral drugs after curative surgery have a lower risk of recurrence compared to those who do not receive antiviral therapy, according to the results of a study published in the Journal of the... Continue Reading

Sutent® Not Effective for Advanced Liver Cancer (July 10, 2009)

In a Phase II clinical trial, patients with inoperable, advanced hepatocellular (liver) cancer did not benefit from treatment with the targeted therapy Sutent® (sunitinib). The results of this study were published in Lancet Oncology. Hepatocellular carcinoma... Continue Reading

Women with Hypothyroidism at Increased Risk of Liver Cancer (June 22, 2009)

Women with Hypothyroidism at Increased Risk of Liver Cancer Long-term hypothyroidism in women significantly increases the risk of developing hepatocellular carcinoma (liver cancer), according to the results of a study published in Hepatology.[1] The liver... Continue Reading

Increased Risk of Liver Cancer for Patients with Cirrhosis Who Overexpress EGF (March 8, 2009)

Increased Risk of Liver Cancer for Patients with Cirrhosis Who Overexpress EGF According to an article recently published in the Journal of the American Medical Association, patients with cirrhosis of the liver who overexpress epithelial growth factor... Continue Reading

Nexavar® Added to Treatment Guidelines for Liver Cancer (March 8, 2009)

Nexavar® Added to Treatment Guidelines for Liver Cancer The drug Nexavar® (sorafenib) has been added to the list of treatment options for patients with liver cancer who are not eligible for a liver transplant. This was reported in a recent presentation... Continue Reading

More Hepatocellular Carcinoma Liver Cancer

Recurrent Liver Cancer

Liver Cancer Drug Livatag® Granted U.S. Food and Drug Administration Fast Track Designation (May 27, 2014)

The drug Livatag® (doxorubicin Transdrug™) has received fast-track designation from the U.S. Food and Drug Administration (FDA) for the treatment of primary liver cancer after treatment with Nexavar® (sorafenib). This was recently announced in a press... Continue Reading

Cabozantinib Shows Promise against Bone Metastases (May 31, 2011)

The investigational drug cabozantinib is showing promise against several types of advanced cancer, and may also reduce or eliminate bone metastases (cancer that has spread to the bone) in some patients. These results will be presented at the 2011 annual... Continue Reading

Study Evaluates Whole-brain Radiation Following Surgery or Radiosurgery in Cancer Spread to the Brain (November 16, 2010)

Results from a randomized Phase III study indicate that whole-brain radiation therapy (WBRT) following removal of one to three brain metastases with surgery or radiosurgery does not improve overall survival or duration of functional independence but does... Continue Reading

More Recurrent Liver Cancer

Screening/Prevention Liver Cancer

Hepatitis C Cases Could Be Cured By Novel Oral Drug Regimen (July 31, 2014)

According to the results of two new clinical studies published in The Lancet, two new pill-only antiviral drug regimens for hepatitis C virus infection provide shorter and more effective treatment options with fewer side effects for most patients affected... Continue Reading

Coffee Cuts Risk of Liver Cancer (November 8, 2013)

Good news for coffee addicts—new research has found that regular coffee consumption can reduce the risk of liver cancer by 40 percent. In fact, the study—published in Clinical Gastroenterology and Hepatology—found that people who consume more than... Continue Reading

Statins Linked to Lower Risk of Liver Cancer in Hepatitis C (May 8, 2013)

People infected with chronic hepatitis C are less likely to develop liver cancer if they are taking statins (cholesterol-lowering drugs), according to the results of a study published in the Journal of Clinical Oncology.[1] The liver is the largest organ... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

Organ Transplant Recipients Have Increased Cancer Risk (November 9, 2011)

People who have received a solid organ transplant (such as a kidney or liver) are twice as likely as people in the general population to develop cancer. These results were published in the Journal of the American Medical Association. In 2010, more than... Continue Reading

More Screening/Prevention Liver Cancer

Stage IV Liver Cancer

Liver Cancer Drug Livatag® Granted U.S. Food and Drug Administration Fast Track Designation (May 27, 2014)

The drug Livatag® (doxorubicin Transdrug™) has received fast-track designation from the U.S. Food and Drug Administration (FDA) for the treatment of primary liver cancer after treatment with Nexavar® (sorafenib). This was recently announced in a press... Continue Reading

Nexavar Superior to Sutent in Liver Cancer (June 23, 2011)

Nexavar® (sorafenib) provides superior overall survival to Sutent® (sunitinib) in the treatment of hepatocellular (liver) cancer. These results were presented at the 2011 annual American Society of Clinical Oncology (ASCO) meeting. Hepatocellular carcinoma... Continue Reading

Cabozantinib Shows Promise against Bone Metastases (May 31, 2011)

The investigational drug cabozantinib is showing promise against several types of advanced cancer, and may also reduce or eliminate bone metastases (cancer that has spread to the bone) in some patients. These results will be presented at the 2011 annual... Continue Reading

FDA Grants Orphan Drug Status to Investigational Liver Cancer Drug (May 2, 2011)

PV-10—an investigational liver cancer drug—has been designated an orphan drug by the US Food and Drug Administration (FDA). The orphan drug designation is intended to encourage the development of drugs for rare diseases by providing incentives for... Continue Reading

Study Evaluates Whole-brain Radiation Following Surgery or Radiosurgery in Cancer Spread to the Brain (November 16, 2010)

Results from a randomized Phase III study indicate that whole-brain radiation therapy (WBRT) following removal of one to three brain metastases with surgery or radiosurgery does not improve overall survival or duration of functional independence but does... Continue Reading

More Stage IV Liver Cancer

Stages I-III Liver Cancer

Antiviral Therapy May Reduce the Risk of Tumor Recurrence in HBV-Related Liver Cancer (November 26, 2012)

Patients with hepatitis B-related liver cancer who receive antiviral drugs after curative surgery have a lower risk of recurrence compared to those who do not receive antiviral therapy, according to the results of a study published in the Journal of the... Continue Reading

Nexavar Superior to Sutent in Liver Cancer (June 23, 2011)

Nexavar® (sorafenib) provides superior overall survival to Sutent® (sunitinib) in the treatment of hepatocellular (liver) cancer. These results were presented at the 2011 annual American Society of Clinical Oncology (ASCO) meeting. Hepatocellular carcinoma... Continue Reading

Combination Chemotherapy Improves Survival with Biliary Tract Cancer (May 17, 2010)

According to the results of a Phase III clinical trial, treatment of locally advanced or metastatic biliary tract cancer with a combination of Gemzar® (gemcitabine) and cisplatin results in better survival and a lower risk of cancer progression than... Continue Reading

Sutent® Not Effective for Advanced Liver Cancer (July 10, 2009)

In a Phase II clinical trial, patients with inoperable, advanced hepatocellular (liver) cancer did not benefit from treatment with the targeted therapy Sutent® (sunitinib). The results of this study were published in Lancet Oncology. Hepatocellular carcinoma... Continue Reading

Differences in IMRT Radiation Doses May Complicate Study Results in Liver Cancer (March 8, 2009)

Differences in IMRT Radiation Doses May Complicate Study Results in Liver Cancer Differences between the prescribed dose of radiation in intensity modulated radiation therapy (IMRT) and the dose that’s actually delivered may make comparison studies... Continue Reading

More Stages I-III Liver Cancer